SWI/SNF aberrations sensitize pancreatic cancer cells to DNA crosslinking agents

While gemcitabine has been the mainstay therapy for advanced pancreatic cancer, newer combination regimens (e.g. FOLFIRINOX) have extended patient survival, though carry greater toxicity. Biomarkers are needed to better stratify patients for appropriate therapy. Previously, we reported that one-thir...

Descripción completa

Detalles Bibliográficos
Autores principales: Davidson, Jean, Shen, Zhewei, Gong, Xue, Pollack, Jonathan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839388/
https://www.ncbi.nlm.nih.gov/pubmed/29515757
http://dx.doi.org/10.18632/oncotarget.20033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839388/
https://www.ncbi.nlm.nih.gov/pubmed/29515757
http://dx.doi.org/10.18632/oncotarget.20033

Ejemplares similares